Development of Biodegradable Injectable In situ Forming Implants for Sustained Release of Lornoxicam

Author(s): Ruby Christian, Vaishali Thakkar*, Tushar Patel, Mukesh Gohel, Lalji Baldaniya, Purvi Shah, Tosha Pandya, Tejal Gandhi.

Journal Name: Current Drug Delivery

Volume 16 , Issue 1 , 2019

Submit Manuscript
Submit Proposal

Graphical Abstract:


Abstract:

Objective: The focus of this study was to develop in situ injectable implants of Lornoxicam which could provide sustained drug release.

Methods: Biodegradable in situ injectable implants were prepared by polymer precipitation method using polylactide-co-glycolide (PLGA). An optimized formulation was obtained on the basis of drug entrapment efficiency, gelling behavior and in vitro drug release. The compatibility of the formulation ingredients were tested by Fourier transform infrared (FT-IR) spectroscopy, and differential scanning colorimetry (DSC). SEM study was performed to characterize in vivo behavior of in situ implant. Pharmacokinetic study and in vivo gelling study of the optimized formulation were performed on Sprague-Dawley rats. Stability testing of optimized formulation was also performed.

Results: The drug entrapment efficiency increased and burst release decreased with an increase in the polymer concentration. Sustained drug release was obtained up to five days. SEM photomicrographs indicated uniform gel formation. Chemical interaction between the components of the formulation was not observed by FT-IR and DSC study. Pharmacokinetic studies of the optimized formulation revealed that the maximum plasma concentration (Cmax), time to achieve Cmax (Tmax) and area under plasma concentration curve (AUC) were significantly higher than the marketed intramuscular injection of lornoxicam. Stability study of optimized batch showed no change in physical and chemical characteristics.

Conclusion: Lornoxicam can be successfully formulated as in situ injectable implant that provides long-term management of inflammatory disorders with improved patient compliance.

Keywords: Osteoarthritis, lornoxicam, PLGA, in situ injectable implant, in vivo study, biodegradable.

[1]
Choubey, J.; Patel, A.; Verma, M. Phytotherapy in the treatment of arthritis: A review. Int. J. Pharma. Res. Sch, 2013, 4, 2853-2865.
[2]
McCabe, C.J.; Akehurst, R.L.; Kirsch, J.; Whitfield, M.; Backhouse, M.; Woolf, A.D.; Scott, D.L.; Emery, P.; Haslock, I. Choice of NSAID and management strategy in rheumatoid arthritis and osteoarthritis. The impact on costs and outcomes in the UK. Pharmacoeconomics, 1998, 14, 191-199.
[3]
Prasad, B.D.; Medhi, B.; Prakash, A.; Patyar, S.; Wadhwa, S. Lornoxicam: A newer NSAID. Indian J. Phys. Med. Rehabil., 2009, 20, 27-31.
[4]
Frizziero, L.; Focherini, M.; Valentini, M.; Reta, M.; Rocchi, P. Long term study on the efficacy and safety of lornoxicam in rheumatoid arthritis. Minerva Med., 2002, 93, 315-320.
[5]
Suleyman, H.; Demircan, B.; Karagoz, Y. Anti-inflammatory and side effects of cyclooxygenase inhibitors. Pharmacol. Rep., 2007, 59, 247-258.
[6]
Tyagi, L.K.; Kori, L.M. Stability study and in-vivo evaluation of lornoxicam loaded ethyl cellulose microspheres. Int. J. Pharm. Sci. Drug Res., 2014, 6, 26-30.
[7]
Dissertationen Online Der Freien Universität Berlin. http://www.diss.fuberlin.de/diss/receive/FUDISS_thesis_000000023117/ (Accessed On: 07.08.16)
[8]
Tipton, A.; Fujita, S.; Frank, K.; Dunn, R. A biodegradable injectable delivery system for nonsteroidal anti-inflammatory drugs. Pharm. Res., 1991, 8, 196-198.
[9]
Dhakal, P.; Khadka, D.; Acharya, A. Formulation and evaluation of transdermal gel of lornoxicam and its delivery by passive and inotophoresis method: A comparative study. Int. J. Pharm. Res. Sch, 2015, 7, 810-818.
[10]
Allah, A.; Kamel, O.; Sammour, O. Injectable long acting chitosan/tripolyphosphate microspheres for the intra-articular delivery of lornoxicam: Optimization and in vivo evaluation. Carbohydr. Polym., 2016, 149, 263-273.
[11]
Zhiyue, Z.; Guihua, H. Intra-articular lornoxicam loaded PLGA microspheres: Enhanced therapeutic efficiency and decreased systemic toxicity in the treatment of osteoarthritis. Drug Deliv., 2012, 19, 255-263.
[12]
Madan, M.; Bajaj, A.; Lewis, S.; Udupa, N.; Baig, J. In situ forming polymeric drug delivery systems. Indian J. Pharm. Sci., 2009, 71, 242-245.
[13]
Mownika, G.; Srinivas, P. Formulation and evaluation of simvastatin injectable in situ implants. Am. J. Drug Discov. Dev, 2012, 2, 87-100.
[14]
Camargo, J.; Sapin, A.; Nouvel, C.; Daloz, D.; Leonard, M.; Bonneaux, F.; Six, J.L.; Maincent, P. Injectable PLA-based in situ forming implants for controlled release of Ivermectin a BCS Class II drug: Solvent selection based on physico-chemical characterization. Drug Dev. Ind. Pharm., 2013, 39, 146-155.
[15]
Kapoor, D.N.; Katare, O.P.; Dhawan, S. In situ forming implant for controlled delivery of an anti-HIV fusion inhibitor. Int. J. Pharm., 2012, 426, 132-143.
[16]
Islam, S. Lipophilic and hydrophilic drug loaded PLA/PLGA in situ implants: Studies on thermal behavior of drug & polymer and observation of parameters influencing drug burst release with corresponding effects on loading efficiency & morphology of implants. Int. J. Pharm. Pharm. Sci., 2011, 3, 181-188.
[17]
Ahmed, A.; Ibrahim, M.; Samy, A.M.; Kaseem, A.; Nutan, M.T.; Hussain, M.D. Biodegradable injectable in situ implants and microparticles for sustained release of montelukast: In vitro release, pharmacokinetics, and stability. AAPS PharmSciTech, 2014, 15, 772-780.
[18]
Zhang, Y.; Huo, M.; Zhou, J.; Xie, S. PKSolver: An add-in program for pharmacokinetic and pharmacodynamics data analysis in microsoft excel. Comput. Methods Prog. Biomed., 2010, 99, 306-314.
[19]
FDA Guidance: Guidance for Industry. Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims, http://www.fda.gov/downloads/Drugs/Guidance ComplianceRegulatoryInformation/Guidances/UCM193282.pdf (Accessed On: 07.08.16).
[20]
Joshi, R.; Arora, V.; Desjardins, J.; Robinson, D.; Himmelstein, K.J.; Iversen, P.L. In vivo properties of an in situ forming gel for parenteral delivery of macromolecular drugs. Pharm. Res., 2008, 15, 1189-1195.
[21]
Zolnik, B.S.; Burgess, D.J. Evaluation of in vivo-in vitro release of dexamethasone from PLGA microspheres. J. Control. Release, 2008, 19(5), 137-145.
[22]
Patel, N.; Thakkar, V.; Moradiya, P.; Gandhi, T.; Gohel, M. Optimization of curcumin loaded vaginal in-situ hydrogel by box-behnken statistical design for contraception. J. Drug Deliv. Sci. Technol., 2015, 29, 55-69.
[23]
Gad, H.A.; El-Nabarawi, M.A.; El-Hady, S.A. Formulation and evaluation of PLA and PLGA in situ implants containing secnidazole and/or doxycycline for treatment of periodontitis. AAPS PharmSciTech, 2008, 9, 878-884.
[24]
Tang, Y.; Singh, J. Controlled delivery of aspirin: Effect of aspirin on polymer degradation and in vitro release from PLGA based phase sensitive systems. Int. J. Pharm., 2008, 357(1-2), 119-125.
[25]
Gabor, F.; Ertl, B.; Wirth, M.; Mallinger, R. Ketoprofen-poly(D,L-lactic-co-glycolic acid) microspheres: Influence of manufacturing parameters and type of polymer on the release characteristics. J. Microencapsul., 1999, 16, 1-12.
[26]
Deepthi, P.R.; Prasad, V.; Diwan, P.V. Preparation and in-vitro evaluation of donepezil hydrochloride sustained release matrix tablets using non-gelling polymer. J. Build. Perform. Simul., 2014, 9, 83-91.
[27]
Hamoudi-Ben Yelles, M.C.; Tan, V.T.; Danede, F.; Willart, J.F.; Siepmann, J. PLGA implants: How Poloxamer/PEO addition slows down or accelerate polymer degradation and drug release. J. Control. Drug Release, 2017, 253, 19-29.


Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 16
ISSUE: 1
Year: 2019
Page: [66 - 78]
Pages: 13
DOI: 10.2174/1567201815666180927155710
Price: $58

Article Metrics

PDF: 22
HTML: 5
EPUB: 1
PRC: 1